Solid growth thanks to operational strength
Geistlich Pharma AG looks back at a successful and eventful 2013. The Swiss family-run company again increased its turnover compared to the previous year and the growth rate was in the high one-digit range. The dental field, where Geistlich Pharma AG was able to maintain its position as a global market leader, and the orthopaedics field developed particularly positively. The latter even grew slightly more strongly than the dental field, even if at a smaller level. In the medical field (pharmaceuticals), successes were achieved with the products for infectiology (Taurolin® and TauroSept®) and for scar treatment (Kelosoft®). With a view to the markets, the Swiss family-run company grew particularly strongly in the BRIC countries Brazil and Russia as well as in the US. The positive economic market environment played a role here, and the demand for products from Geistlich Pharma AG was accordingly high. In China, Korea and Europe, the market in the field of regenerative dental medicine was hotly contested. Another factor was the economic uncertainty in some EU countries. Nevertheless, Geistlich Pharma AG succeeded in maintaining its leading position in these markets too and in most cases even generating single-digit growth.
New products strengthen the business divisions
The goal of Geistlich Pharma AG is to drive its three business divisions Dental, Orthopaedics and Medical forward with notable investments in research and science. With this in mind, the company expanded the product portfolio considerably also in 2013. In the field of regenerative dental medicine, Geistlich Pharma AG launched a collagen matrix - Geistlich Mucograft® Seal. In addition, another success was achieved in Japan: After Geistlich Bio-Oss®, Geistlich Bio-Gide® has also been approved by the Japanese authorities and was introduced on the market at the end of the year. In the Orthopaedics division, Geistlich Pharma AG launched the new application AMIC® Hip in combination with the product Chondro-Gide® for cartilage regeneration. In the Medical business division, the development of a new product range was commenced that draws on the company's long-standing collagen expertise. With regard to research, particular highlights were the ten-year anniversary of the Osteology Foundation which was launched by Dr Peter Geistlich in 2003, as well as the new establishment of the Osteo Science Foundation in the US. The Osteology Foundation was set up to promote research in regenerative dental medicine and to make it accessible to practice. Numerous partnerships in partnership, practice and industry have since facilitated the development of improved therapy approaches for patients. The goal of the newly established Osteo Science Foundation is to support independent research in North America in oral and maxillofacial surgery and to put its results from theory into practice.
Geistlich culture as the cornerstone for success
Not only the geographical breadth or the newly launched products are decisive for the continuous growth of Geistlich Pharma AG. Geistlich Pharma AG owes the growth not least to its employees. Their motivation and commitment, coupled with a high level of specialist know-how, form the basis for the company's success. In this spirit, Geistlich Pharma AG attaches great importance to a corporate culture that promotes and respects the employees' commitment to strive for maximum quality at all times. For the 2014 financial year, Geistlich Pharma AG is expecting a market environment that will continue to be challenging. The company is also well positioned for the challenges in the new year and is looking forward to successfully tackling these too.